{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":1,"podcast":1,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT04165772","nct_id":"NCT04165772","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04165772. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients with clinical Stage II or Stage III MRI-staged, MSI-H or dMMR, solid tumors will receive up to 6 months (9, 21-day cycles) of PD-1 blockade followed by radiological and surgical restaging of the tumor. If subject exhibits complete clinical response, non-operative management will be followed. If a complete clinical response is not reached after 6 months of PD-1 blockade, the participant will proceed with standard chemoradiation. After completing chemoradiation participant will be assessed for response if complete CR is not obtained then the participant will proceed with disease specific surgical resection or standard of care therapy.","label":"Cohort 1","type":"EXPERIMENTAL"},{"description":"The plan is to enroll six patients with MSI, regardless of their primary cancer diagnosis. This cohort will serve to generate hypothesis and initial data to plan a larger study. All analyses from this cohort will be exploratory","label":"Cohort 2","type":"OTHER"},{"description":"Participants with FIGO Stage I or II mismatch repair deficient (MMRd) and/or microsatellite instability high (MSI-H) endometrial cancer will receive intravenous dostarlimab.","label":"Cohort 3","type":"OTHER"}],"collaborators":["Tesaro, Inc."],"completion_date":{"date":"2026-11-30","type":"ESTIMATED"},"conditions":["Rectal Adenocarcinoma","Clinical Stage: Stage II (T3-4, N-)","Stage III (Any T, N+)","Solid Tumor","Solid Tumor, Adult"],"enrollment":{"count":212,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"TSR-042 or Dostarlimab","type":"DRUG"},{"name":"capecitabine or 5-FU","type":"DRUG"},{"name":"Intensity Modulated Radiation Therapy (IMRT)","type":"RADIATION"}],"last_update":"2026-09-15","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-11-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Pathologic complete response (pCR) or complete clinical response (cCR) at 12 months","timeFrame":"12 months"}],"references":[{"citation":"Cercek A, Foote MB, Rousseau B, Smith JJ, Shia J, Sinopoli J, Weiss J, Lumish M, Temple L, Patel M, Wilde C, Saltz LB, Argiles G, Stadler Z, Artz O, Maron S, Ku G, Gu P, Janjigian YY, Molena D, Iyer G, Coleman J, Abida W, Cohen S, Soares K, Schattner M, Strong VE, Yaeger R, Paty P, Shcherba M, Sugarman R, Romesser PB, Zervoudakis A, Desai A, Segal NH, El Dika I, Widmar M, Wei I, Pappou E, Fumo G, Aparo S, Gonen M, Gollub M, Jayaprakasam VS, Kim TH, Garcia Aguilar J, Weiser M, Diaz LA Jr. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med. 2025 Jun 19;392(23):2297-2308. doi: 10.1056/NEJMoa2404512. Epub 2025 Apr 27.","pmid":"40293177","type":"DERIVED"},{"citation":"Saude-Conde R, Nguyen D, Hendlisz A. Immunotherapies in non-metastatic gastrointestinal cancers. Curr Opin Oncol. 2023 Jul 1;35(4):334-346. doi: 10.1097/CCO.0000000000000956. Epub 2023 May 9.","pmid":"37222204","type":"DERIVED"},{"citation":"Costa B, Vale N. Dostarlimab: A Review. Biomolecules. 2022 Jul 26;12(8):1031. doi: 10.3390/biom12081031.","pmid":"35892341","type":"DERIVED"},{"citation":"Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA Jr. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 2022 Jun 5.","pmid":"35660797","type":"DERIVED"}],"start_date":{"date":"2019-12-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors","url":"https://clinicaltrials.gov/study/NCT04165772"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04165772"}